One License for Three Platforms
Biocytogen provides RenMab™, RenLite™ and RenNano™ mouse platforms that are powerful tools for generating fully human antibodies in various formats, including bispecific, multispecific, heavy chain only antibody and nanobody. One license covers all three platforms.
Related Resources
Events
- Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA | July 07, 2021
- Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars | June 22, 2021
- Celebrating World CRISPR Day | October 29, 2020
- Webinar: Antibody Discovery Platforms and RenMab Mouse | June 29, 2020
- Webinar: Humanized Animal Models for Immunotherapy | June 29, 2020
- Experts in Genetically Engineered Animal Development and Maintenance | September 19, 2019
- Symposium: Future of Biologic Drug Discovery and Development | June 13, 2019
News
- Team Building in the White Mountains | July 27, 2021
- Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA | July 07, 2021
- Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars | June 22, 2021
- Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1 | March 23, 2021
- Biocytogen announces acquisition of a third Beacon Optofluidic system | March 05, 2021
- Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab | February 10, 2021
- Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement | February 01, 2021
- Biocytogen Enters into RenMab™/RenLite™ Licensing Agreement with Xencor | December 07, 2020
- Biocytogen Teams With Ina Research To Boost Presence In Japan | December 04, 2020
- Festival of Biologics Basel 2020 | November 02, 2020
- Immuno-Oncology Summit Virtual Summit 2020 | October 01, 2020
- Emerging biotechnology company Biocytogen raised 142 million dollars (USD) in support of Project Integrum | September 24, 2020
- Strategic collaboration agreement reached between Biocytogen and Berkeley Lights for second Beacon Optofluidic system | September 18, 2020
- PEGS Boston Virtual Summit | August 20, 2020
- RenMab™ and RenLite™ Models Featured in GEN Magazine | August 19, 2020
- RenMab™ Mouse Platform Drives SARS CoV-2 Neutralizing Antibody Cocktail Therapy Towards Clinical Trials in Biocytogen and Eucure Biopharma Partnership | August 13, 2020
- Biocytogen is Featured in GEN’s Immunotherapy and Cancer Supplement Issue | April 10, 2020
- Biocytogen CEO’s Response During COVID-19 Pandemic | April 08, 2020
- Gene Targeting Service Verified with Industry-leading Quality Control Measures | March 12, 2020
- GEN Magazine Mentions Biocytogen and Its Humanized Mice Model | March 06, 2020
- Nature Research Webcast: Accelerating therapeutic antibody discovery with fully human antibody mice | November 26, 2019
- The Utility of the Rosa26 Knock-in Mouse | November 19, 2019
- RenMab™ Mouse Featured in GEN Magazine | November 08, 2019
- Biocytogen’s RenMab™ Mouse is Featured on Fiercebiotech | October 28, 2019
- Biocytogen Closes $79M Series D Funding | August 09, 2019
- Biocytogen’s President & CEO, Dr. Yuelei Shen, Speaks at Harvard China Forum at Harvard University | April 15, 2019
- Biocytogen’s Integrated One-stop Preclinical Services and the RenMab Mouse Shine at AACR 2019 | April 07, 2019
